ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

14 COMMENTS

    Hey there just wanted to give you a quick heads up. The text in your article seem to be running off the screen in Chrome. I’m not sure if this is a format issue or something to do with web browser compatibility but I thought I’d post to let you know. The layout look great though! Hope you get the problem solved soon. Kudos|

    I just like the helpful info you provide in your articles. I will bookmark your weblog and take a look at again here regularly. I am quite certain I will be told a lot of new stuff right here! Good luck for the next!|

    Receive and send emails through your temporary messaging system. Use our webmail or your favorite email software with our absolutely free disposable email. temp mail

    I simply couldn’t leave your site prior to suggesting that I really loved the standard information a person supply in your visitors?

    Is gonna be back continuously to check out new posts

    Howdy! Someone in my Myspace group shared this website with us so I came to check
    it out. I’m definitely enjoying the information. I’m bookmarking and will be tweeting this
    to my followers! Superb blog and amazing design.

    Hey There. I discovered your weblog the usage of msn. That
    is a really neatly written article. I’ll make sure to bookmark it and
    return to read extra of your helpful information. Thank you for the post.

    I will definitely comeback.

    Thanks for finally talking about > ISSAR Pharma Announces Out-Licensing of Its Peptide-Based
    NCEs – India First News < Loved it!

    Unquestionably believe that which you said. Your favorite reason seemed to be on the internet the easiest thing to be aware of.

    I say to you, I definitely get annoyed while people think about
    worries that they plainly do not know about. You managed
    to hit the nail upon the top and defined out the whole thing without having side effect , people could take a signal.
    Will probably be back to get more. Thanks

    Great blog here! Also your web site lots up very fast!
    What host are you the use of? Can I get your associate link for your host?
    I wish my website loaded up as fast as yours lol

Leave a Reply

Your email address will not be published.